

## **Biofrontera to Present at Two Upcoming Investor Conferences**

**Leverkusen, Germany, June 12, 2019** – Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced that Thomas Schaffer, Biofrontera’s Chief Financial Officer, is scheduled to present at two upcoming investor conferences.

Details of the presentations are below:

Event: Raymond James Life Sciences and MedTech Conference

Date: Wednesday, June 19, 2019

Time: 2:25pm ET

Location: Lotte New York Palace

Event: JMP Securities Life Sciences Conference

Date: Thursday, June 20, 2019

Time: 10:30am ET

Location: The St. Regis New York

Biofrontera’s management team will be available for one-on-one meetings with investors who are registered to attend the event. Alternatively, interested investors may contact Tram Bui of The Ruth Group at [tbui@theruthgroup.com](mailto:tbui@theruthgroup.com) or (646) 536-7035 to schedule a meeting.

**-End-**

**For enquiries, please contact:**

**Biofrontera AG** +49 (0) 214 87 63 2 0

Thomas Schaffer, Chief Financial Officer [ir@biofrontera.com](mailto:ir@biofrontera.com)

**IR UK: Seton Services**

Toni Vallen +44 (0) 207 229 0805

**IR and PR US: The Ruth Group**

IR: Tram Bui +1 646-536-7035

PR: Kirsten Thomas +1 508-280-6592

**About Biofrontera:**

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company’s lead product is the combination of Ameluz®, a topical prescription drug, and

medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets AKTIPAK®, a prescription medication for the treatment of acne, and Xepi™ for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin.

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ. [www.biofrontera.com](http://www.biofrontera.com).

## **Biofrontera AG**

Hemmelrather Weg 201 | D-51377 Leverkusen, Germany  
Phone: +49 214 87632-0 | Telefax: +49 214 87632-90  
[info@biofrontera.com](mailto:info@biofrontera.com) | [www.biofrontera.com](http://www.biofrontera.com)

Supervisory board: Dr. Ulrich Granzer (Chairman) | Jürgen Baumann (Vice-Chairman)  
Executive board: Prof. Dr. rer. nat. Hermann Lübbert (CEO)

Christoph Dünwald (CCO) | Thomas Schaffer (CFO)

**Commercial register:** Handelsregister Köln | **Register number:** HR B 49717 (AG)

**VAT-identification number according to § 27 a UStG VAT act:** DE 812374102